Improving outcomes in advanced malignant melanoma: Update on systemic therapy

Drugs

Volumn 65, Issue 6, 2005, Pages 733-743

  Danson, Sarah ^a   Lorigan, Paul ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTISENSE OLIGONUCLEOTIDE; B RAF KINASE; BCG VACCINE; BENZYLGUANINE; BEVACIZUMAB; CANCER TESTIS ANTIGEN; CANCER VACCINE; CARBOPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPITOPE; FOTEMUSTINE; GANGLIOSIDE; GANGLIOSIDE GM2; GLYCOPROTEIN GP 100; GLYCOPROTEIN GP 96; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GUANINE DERIVATIVE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN GLYCOPROTEIN GP 96 COMPLEX; HISTAMINE; IMATINIB; IMIQUIMOD; INTERFERON; INTERLEUKIN 2; IPILIMUMAB; LENALIDOMIDE; LOMEGUATRIB; MELACINE; MELAN A; MELANOMA ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LM 609; MONOPHENOL MONOOXYGENASE; NITROSOUREA DERIVATIVE; OBLIMERSEN; PACLITAXEL; PEPTIDE DERIVATIVE; PLACEBO; PLATINUM DERIVATIVE; PROTEIN NY ESO 1; RESIQUIMOD; SEMAXANIB; SORAFENIB; TAXANE DERIVATIVE; TEMOZOLOMIDE; THALIDOMIDE; TRASTUZUMAB; UNCLASSIFIED DRUG; VINCA ALKALOID; VIRUS RNA; VITRONECTIN RECEPTOR ANTIBODY; X LINKED INHIBITOR OF APOPTOSIS;

ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA VECTOR; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG TOLERABILITY; GENE DELIVERY SYSTEM; GENE THERAPY; HUMAN; LOW DRUG DOSE; LYMPHOCYTOPENIA; MELANOMA; METASTASIS; MONOTHERAPY; NEUROPATHY; OPPORTUNISTIC INFECTION; QUALITY OF LIFE; RASH; REVIEW; SIDE EFFECT; VERRUCA VULGARIS; VIRAL GENE DELIVERY SYSTEM;

ANTINEOPLASTIC AGENTS; HUMANS; MELANOMA; TREATMENT OUTCOME;

EID: 17844374616     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200565060-00002     Document Type: Review

References (91)

1. De Vries E, Bray FI, Coebergh JW, et al. Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: rising trends in incidence and mortality but recent stabilisations in Western Europe and decreases in Scandanavia. Int J Cancer 2003; 107 (1): 119-26
2. MacKie RM, Bray CA, Hole DJ, et al. Incidence of and survival from malignant melanoma in Scotland: an epidemiological study. Lancet 2002; 360: 587-91
3. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5-26
4. Giles D, Dwyer T, Coates M, et al. Trends in skin cancer in Australia: an overview of the available data. Trans Menzies Found 1989; 15: 143-7
5. Morton DL, Essner R, Calch C. Surgical excision of distant metastases. In: Balch C, Houghton A, Sober A, et al., editors. Cutaneous melanoma. 4th ed. St Louis (MO): Quality Medical Publishing, 2003: 547-72
6. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-48
7. Middleton MR, Grob JJ, Aaronson N, et al. Randomised phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic melanoma. J Clin Oncol 2000; 18: 158-66
8. Millward MJ, Bedikian AY, Conry RM, et al. Randomised multinational phase 3 trial of dacarbazine with or without bcl-2 antisense (oblimersan sodium) in patients with advanced malignant melanoma: analysis of long-term survival [abstract no. 7505]. Proc Am Soc Clin Oncol 2004; 22 (145): 22
9. Lee SM, Betticher DC, Thatcher N. Melanoma: chemotherapy. Br Med Bull 1995; 51: 609-30
10. Luikart SD, Kennealey GT, Kirkwood JM. Randomised phase III trial of vinblastine, bleomycin and cis-dichlorodiamine-platinum versus dacarbazine in malignant melanoma. J Clin Oncol 1984; 2: 164-8
11. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicentre randomised trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17: 2745-51
12. Middleton M, Lorigan P, Owen J, et al. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer 2000 82: 1158-62
13. Legha SS. The role of interferon alpha in the treatment of metastatic melanoma. Semin Oncol 1997; 24 (4 Suppl.): S24-31
14. Agarwala SS, Glaspy J, O'Day SJ, et al. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 2002; 20: 125-33
15. Atkins MB, Lotze MT, Dutcher JP, et al. High dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17: 2105-16
16. Margolin K, Atkins M, Sparano J, et al. Prospective randomised trial of lisofylline for the prevention of toxicities of high dose interleukin-2 therapy in advanced renal cancer and malignant melanoma. Clin Cancer Res 1997; 3: 365-72
17. Falkson C, Falkson G, Falkson H. Improved results with the addition of interferon alpha-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 1991; 9: 1403-8
18. Huncharek M, Caubet JF, McGarry R. Single-agent dacarbazine versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 2001; 11: 75-81
19. Keilholz U, Conradt C, Legha SS, et al. Results of interleukin-2 based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol 1998; 16 (9): 2921-9
20. Ernstoff MS. Update: medical therapy for cutaneous melanoma [oral presentation]. American Society of Clinical Oncology (ASCO) 39th Annual Meeting; 2003 May 31-Jun 3; Chicago
21. Del Vecchio M, Bajetta E, Vitali M, et al. Multicentre phase III randomised trial of cisplatin, vindesine and dacarbazine (CVD) versus CVD plus subcutaneous (sc) interleukin-2 (IL-2) and interferon-alpha-2b (IFN) in metastatic melanoma patients (pts) [abstract no. 2849]. American Society of Clinical Oncology (ASCO) 39th Annual Meeting; 2003 May 31-Jun 3; Chicago
22. Keilholz U, Punt CJ, Gore M, et al. Dacarbazine, cisplatin and IFN-alpha-2b with or without IL-2 in advanced melanoma: final analysis of EORTC randomised phase III trial 18951 [abstract no. 2848]. American Society of Clinical Oncology (ASCO) 39th Annual Meeting; 2003 May 31-Jun 3; Chicago
23. Atkins MB, Lee S, Flaherty LE, et al. A prospective randomised phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD) IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): an ECOG-coordinated intergroup trial [abstract no. 2847]. Proc Am Soc Clin Oncol 2003; 22: 708
24. Newlands ES, Blackledge GR, Slack JA, et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 1992; 65: 287-91
25. Bleehan NM, Newlands ES, Lee SM, et al. Cancer Research Campaign phase II trial of temozolomide in malignant melanoma. J Clin Oncol 1995; 13: 910-3
26. Lee SM, Thatcher N, Crowther D, et al. Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br J Cancer 1994; 69: 452-6
27. Su YB, Sohn S, Krown SE, et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 2004; 22 (3): 610-6
28. Yung WK, Levin VA, Albright J, et al. A phase II study of temozolomide vs procarbazine in glioblastoma multiforme at first relapse. Br J Cancer 2000; 83: 588-93
29. Villa S, Verger E, Gil M, et al. Concomitant and adjuvant temozolomide and whole brain irradiation on patients affected with brain metastases: a randomised multicentre phase II trial. Int J Radiat Oncol 2003; 57 (2 Suppl.): S132
30. Stupp R, Mason WP, Van Den Bent MJ, et al. Concomitant and adjuvant temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme: conclusive results of a randomised phase III trial by the EORTC brain and RT groups and NCIC clinical trials group [abstract no. 2]. Proc Am Soc Clin Oncol 2004; 22 (145): 15
31. Paul MJ, Summers Y, Calvert H, et al. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res 2002; 12 (2): 175-8
32. Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 2004; 22: 2101-7
33. Kleeburg UR, Engel E, Israels P, et al. Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and effectiveness: a multi-centre phase II trial of the EORTC-melanoma cooperative group (MCG). Melanoma Res 1995; 5: 195-200
34. Avril MF, Aamdal S, Grob JJJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004; 22: 1118-25
35. 6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study. Int J Cancer 2000; 88 (3): 469-73
36. Dolan ME, Posner M, Karrison T, et al. Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically respectable tumours. Clin Cancer Res 2002; 8: 2519-23
37. Tentori L, Leonetti C, Scarsella M, et al. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumour activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res 2003; 9: 5370-9
38. Hu Y, Cherton-Horvat G, Dragowska V, et al. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res 2003; 9 (7): 2826-36
39. Amiri KI, Horton LW, LaFleur BJ, et al. Augmenting chemosensitivity of malignant melanoma tumours via proteasome inhibition: implication for bortezomib (VEL-CADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res 2004; 64: 4912-8
40. Eisen T, Boshoff C, Mak I, et al. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000; 14 (13 Suppl.): 17-20
41. Danson S, Lorigan P, Arance A, et al. A randomised study of temozolomide (TMZ) alone, with interferon (TMZ-IFN) or with thalidomide (TMZ-THAL) in metastatic malignant melanoma (MMM). J Clin Oncol 2003; 21 (13): 2551-7
42. Hwu WJ, Krown SE, Menell JH, et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 2003; 21 (17): 3351-6
43. Dredge K, Marriott JB, Macdonald CD, et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 2002; 87 (10): 1166-72
44. Bartlett JB, Michael A, Clarke IA, et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of the thalidomide analogue CC-5013 in patients with metastatic melanoma and other advanced cancers. Br J Cancer 2004; 90 (5): 955-61
45. Tucker GC. Alpha v integrin inhibitors and cancer therapy [erratum appears in Curr Opin Investig Drugs 2003; 4: 1140]. Curr Opin Investig Drugs. 2003 Jun; 4 (6): 722-31
46. Tucker GC. Alpha v integrin inhibitors and cancer therapy [erratum appears in Curr Opin Investig Drugs 2003; 4: 1140]. Curr Opin Investig Drugs. 2003 Jun; 4 (6): 722-31
47. Peterson AC, Swiger S, Stadler W, et al. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in patients with advanced melanoma [abstract no. 2863]. Proc Am Soc Clin Oncol 2003; 22: 712
48. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal carcinoma. N Engl J Med 2004; 350 (23): 2335-42
49. Carsons WE, Biber J, Shah N, et al. A phase 2 trial of a recombinant humanised monoclonal anti-vascular endothelial growth factor (VEGF) antibody in patients with malignant melanoma [abstract no. 2873]. Proc Am Soc Clin Oncol 2003; 22: 715
50. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54
51. Casula M, Colombino M, Satta MP, et al. BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: the Italian Melanoma Intergroup Study. J Clin Oncol 2004; 22 (2): 286-92
52. Rivets JK. Is there more than one road to melanoma? Lancet 2004; 363: 728-30
53. V599E in human melanoma abrogates transformation. Cancer Res 2003; 63: 5198-202
54. Collisson EA, De A, Suzuki H, et al. Treatment of metastatic melanoma with an orally available inhibitor of the ras-raf-MAPK cascade. Cancer Res 2003; 63: 5669-73
55. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumour activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumour progression and angiogenesis. Cancer Res 2004; 64: 7099-109
56. Ahmad T, Marais R, Pyle L, et al. BAY 43-9006 in patients with advanced melanoma: the Royal Marsden experience [abstract no. 7506]. Proc Am Soc Clin Oncol 2004; 22 (145): 7115
57. Flaherty KT, Brose M, Schuchter L, et al. Phase I/II trial of BAY 43-9006, carboplatin and paclitaxel demonstrates preliminary antitumour activity in the expansion cohort patients with metastatic melanoma [abstract no. 7507]. Proc Am Soc Clin Oncol 2004; 22 (145): 7115
58. Sparrow LE, Heenan PJ. Differential expression of epidermal growth factor receptor melanocytic tumours demonstrated by immunohistochemistry and mRNA in situ hybridization. Australas J Dermatol 1999; 40 (1): 19-24
59. Inman JL, Kute T, White W. Absence of HER2 overexpression in metastatic malignant melanoma. J Surg Oncol 2003; 84 (2): 82-8
60. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukaemia. N Engl J Med 2001; 344: 1031-7
61. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumours. N Engl J Med 2002; 347: 472-80
62. Janku F, Tomancova V, Novotny J, et al. Expression of c-kit was found in more than 50% of early stages melanoma: a retrospective study of 261 patients [abstract no. 2864]. Proc Am Soc Clin Oncol 2003; 22: 712
63. Wyman K, Atkins MB, Hubbard F, et al. A phase II trial of imatinib mesylate at 800mg daily in metastatic melanoma: lack of clinical efficacy with significant toxicity [abstract no. 2865]. Proc Am Soc Clin Oncol 2003; 22: 713
64. National Cancer Institute (NCI). Clinical trials [online]. Available from URL: www.cancer.gov/search/clinicaltrials [Accessed 2005 Feb 2]
65. Hansson M, Hermodsson S, Brune M, et al. Histamine protects T cells and natural killer cells against oxidative stress. J Interferon Cytokine Res 1999; 19: 1135-44
66. Asea A, Hermodsson S, Hellstrand K. Histaminergic regulation of natural killer cell-mediated clearance of tumour cells in mice. Scand J Immunol 1996; 43: 9-15
67. Hellstrand K, Naredi P, Lindner P, et al. Histamine in immunotherapy of advanced melanoma: a pilot study. Cancer Immunol Immunother 1994; 39: 416-9
68. Maxim Pharmaceuticals Press Conference. Maxim Pharmaceutical phase 3 trial for advanced melanoma fails to meet primary endpoint [media release]. 2004 Sep 20
69. Hauschild A. First analysis of international M-02 trial: histamine, interferon alpha-2b (IFN), interleukin (IL)-2 vs dacarbazine (DTIC) [oral presentation]. European conference: Perspectives in Melanoma Management; 2003 Oct 10-11; Amsterdam
70. Sosman JA, Weeraranta AT, Sondak VK. When will melanoma vaccines be proven effective? J Clin Oncol 2004; 22 (3): 387-9
71. Livingstone PO, Wong GY, Adluri S, et al. Improved survival in stage III melanoma patients with GM2 antibodies, a randomised trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994; 5: 1036-44
72. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High dose interferon alpha 2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of inter-group trial E1694/S9512/C509801. J Clin Oncol 2001; 19 (9): 2370-80
73. Marchard M, von Baren N, Weynants P, et al. Tumour regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999; 80: 219-30
74. Cebon J, Jager E, Shackleton MJ, et al. Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenze peptides in subjects with advanced malignant melanoma. Cancer Immun 2003; 16: 3-7
75. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4: 321-7
76. Kirkwood J, Lee S, Land S, et al. E1696: final analysis of the clinical and immunological results of a multi-centre ECOG phase II trial of multi-epitope peptide vaccination for stage IV disease with MART-1, gp1000 and tyrosinase [abstract no. 7502]. Proc Am Soc Clin Oncol 2004; 22 (145): 7105
77. David I, Chen W, Jackson H, et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A 2004; 101: 10697-702
78. Sosman JA, Unger JM, Liu PY, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumour vaccine: impact of HLA class I antigen expression on outcome. Southwest Oncology Group. J Clin Oncol 2002; 20 (8): 2067-75
79. Morton DL, Eilber FR, Holmes EC, et al. Preliminary results of a randomised trial of adjuvant immunotherapy in patients treated with malignant melanoma who have lymph node metastases. Aust N Z J Surg 1978; 48: 49-52
80. Chan AD, Morton DL. Active immunotherapy with allogeneic tumour cell vaccines: present status. Semin Oncol 1998; 25: 611-22
81. Belli F, Testori A, Rivoltini L, et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 2002; 20 (20): 4169-80
82. Soiffer R, Hodi FS, Haluska F, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003; 21 (17): 3343-50
83. Smith CL, Dunbar PR, Palmowski MJ, et al. Results of a phase I study evaluating 'prime-boost' therapeutic vaccination strategies using a string of melanoma-derived CD8+ T cell epitopes in stage II/III/IV melanoma patients [abstract no. 702]. Proc Am Soc Clin Oncol 2003; 22: 175
84. Smith C, Dunbar P, Mirza F, et al. Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int J Cancer 2005; 113 (2): 259-66
85. Kugler A, Stuhler G, Walden P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumour cell-dendritic cell hybrids. Nat Med 2000; 6: 332-6
86. Bedrosian I, Mick R, Xu S, et al. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol 2003; 21 (20): 3826-35
87. Schadendorf D, Nestle FO, Broecker E-B, et al. Dacarbazine versus vaccination with autologous peptide-pulsed dendritic cells as first-line treatment of patients with metastatic melanoma: results of a prospective-randomised phase III study [abstract no. 7508]. Proc Am Soc Oncol 2004; 22 (145): 7125
88. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumour lymphocytes. Science 2002; 298: 850-4
89. Phan GQ, Yang J, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen4 blockade in patients with metastatic melanoma. Proc Nat Acad Sci U S A 2003; 100: 8372-7
90. Hersh E, Weber J, Powderly J, et al. A phase II randomised multi-centre study of MDX-010 alone or in combination with DTIC in stage IV malignant melanoma [abstract no. 7511]. Proc Am Soc Clin Oncol 2004; 22 (145): 7125
91. Schneeder A, Wagner C, Zemann A, et al. CpG motifs are efficient adjuvants for DNA vaccines. J Invest Dermatol 2004; 123: 371-9